Results 101 to 110 of about 22,015 (248)

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays [PDF]

, 2017
Background: The commercialization of CT-P13, an infliximab (IFX) biosimilar, has the potential to decrease health-related costs and enhance access to biological therapies.
Cláudia Camila Dias, Fernando Magro, Gonczi L, Helena Tavares de Sousa, Isadora Rosa, Joana Afonso, João Carvalho   +6 more
core   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels/antidrug antibody levels or clinical/biochemical markers play a more important role? [PDF]

, 2018
K
Bene, László, Bor, Renáta, Bíró, Edina, Farkas, Klaudia, Gasztonyi, Beáta, Gecse, Krisztina B., Golovics, Petra Anna, Gönczi, Lóránt, Kristóf, Tünde, Kürti, Zsuzsanna, Lakatos, László, Lakatos, Péter László, Lovász, Barbara Dorottya, Miheller, Pál, Molnár, Tamás, Palatka, Károly, Papp, Mária, Patai, Árpád, Rutka, Mariann, Salamon, Ágnes, Szamosi, Tamás, Szepes, Zoltán, Tóth, Gábor Tamás, Vincze, Áron, Végh, Zsuzsanna   +24 more
core  

Investigating the Effect of Tumour Necrosis Factor Antagonist on Olfaction

Clinical Otolaryngology, EarlyView.
ABSTRACT Objectives Tumour Necrosis factor antagonists is a potent anti‐inflammatory medication and has shown to improve olfactory function in murine models. The primary aim was to determine the effect of TNF antagonists on olfactory performance in humans.
Andreas Espehana, George Macfarlane, Elizabeth Mairenn Garden, Liam Lee, Gabija Klyvyte, Lavandan Jegatheeswaran, Rebecca Davies, Carl Philpott   +7 more
wiley   +1 more source

Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy [PDF]

, 2017
Background and Objectives: Considering the clinical and economic burden of biological drugs in cancer treatment, it is necessary to explore how these drugs are used in routine care in Italy and how they affect the sustainability of the National Health ...
Adamo, V. (Vincenzo), Altavilla, G. (Giuseppe), Ferraù, F. (Francesco), Franchina, T. (Tindara), Intelisano, R. (Rosanna), Lucchesi, S. (Simona), Marcianò, I. (Ilaria), Panagia, P. (Paolo), Randazzo, M.P. (Maria Pia), Reitano, P. (Paolina), Santarpia, M. (Mariacarmela), Sgroi, C. (Carmela), Trifirò, G. (Gianluca)   +12 more
core   +2 more sources

Inconsistent standard of care for tuberculosis screening and preventive therapy before initiating systemic psoriasis treatment

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Preventive tuberculosis (TB) therapy before initiating MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors for latent tuberculosis infection (LTBI) is supported by indirect evidence of TB reactivations with TNF inhibitors. However, direct evidence for MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors is limited.
Christoph Zeyen, Ruben Heuer, Brit Haecker, Tom Schaberg, Alexander Nast   +4 more
wiley   +1 more source

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis [PDF]

, 2017
Objective: To compare the 52-week efficacy and safety of SB4 [an etanercept biosimilar] with reference etanercept (ETN) in patients with active RA. Methods: In a phase 3, randomized, double-blind, multicentre study, patients with moderate to severe RA ...
Aaron Alejandro Barrera Rodriguez, Anna Sylwestrzak, Asta Baranauskaite, Barbara Stasiuk, Bathon, Combe, Curtis, Duclos, Emery, Emery, Emery, Emery, Emery, Emery, Emery, Emery, Frazier-Mironer, Genovese, Genovese, Jeehoon Ghil, Jiří Vencovský, Kavanaugh, Kay, Kay, Klareskog, Klareskog, Klareskog, Kuek, Lee, Lopez-Olivo, Moreland, Paul Emery, Piotr Leszczyński, Roma Milasiene, Ruff, Smolen, Smolen, Soo Yeon Cheong, van der Heijde, van der Heijde, Vira Tseluyko, Vyacheslav M. Zhdan, Wieslawa Porawska   +42 more
core   +1 more source

Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word ...
Georgios Kokolakis, Sandra Philipp, Thomas Mosch, Björn Fritz, Robert Sabat   +4 more
wiley   +1 more source

Ten years of clinical experience with biosimilar human growth hormone: a review of safety data

Drug Design, Development and Therapy, 2017
Maria Victoria Borrás Pérez,1 Berit Kriström,2 Tomasz Romer,3 Mieczyslaw Walczak,4 Nadja Höbel,5 Markus Zabransky5 1Hospital General de Granollers, Granollers, Barcelona, Spain; 2Department of Clinical Sciences, Pediatrics, Ume ...
Borrás Pérez MV, Kriström B, Romer T, Walczak M, Höbel N, Zabransky M   +5 more
doaj  

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice ...
Geremia B. Bolli, Philip D. Home, Mauro Lepore, Matthew C. Riddle, Francesca Porcellati, Carmine G. Fanelli, Paola Lucidi, Hannele Yki‐Järvinen, Reinhard H. Becker, David R. Owens   +9 more
wiley   +1 more source